Where your money goes

Supporting breast AND ovarian cancer research in 2024

Over the past 26 years, the Mother's Day Classic community has donated $44 million to fund life-saving breast cancer research.

Thanks to research, the five-year survival rate for breast cancer has increased from 84 per cent to 92 per cent since the Mother’s Day Classic started in 1998. There’s still more to be done to achieve the goal of zero deaths from breast cancer.

Tragically, treatment, early detection, and preventative medical research advances for ovarian cancer have been limited. Treatment options and targeted therapies have only marginally improved in 30 years and there is currently no readily available, non-invasive early detection test for ovarian cancer. The average five year survival rate is just 49 per cent.

This is why the Mother’s Day Classic has decided to go further in 2024 and invite our participants to run or walk in support of ovarian cancer research, in addition to breast cancer research.

Participants in the 2024 Mother's Day Classic event will be provided with the option of taking part in support of and fundraising for breast cancer research, ovarian cancer research or both – it’s up to you!

In 2024 we will partner with both the National Breast Cancer Foundation and the Ovarian Cancer Research Foundation to fund game changing research that is focussed on saving women’s lives.  We will continue to raise funds through community fundraising, online fundraising, donations, merchandise sales and registration fees.

Once event and administration costs have been deducted, proceeds will be donated to the National Breast Cancer Foundation (NBCF) and the Ovarian Cancer Research Foundation (OCRF) to fund life-changing research. Mother's Day Classic Foundation will continue to endeavour to keep costs low, so as much as possible can be donated.

 

NBCF

National Breast Cancer Foundation (NBCF) is Australia’s leading not-for-profit organisation funding world-class breast cancer research towards their vision of Zero Deaths from breast cancer.

LEARN MORE

OCRF

The Ovarian Cancer Research Foundation (OCRF) is Australia’s leading independent organisation dedicated to funding the most innovative ovarian cancer research.

LEARN MORE

GAME CHANGING RESEARCH

Current Research Projects

Read about the current projects that funds raised by  Mother's Day Classic participants around Australia have been used to support. And in 2024 we aim to go further contributing funds to both breast cancer and ovarian cancer reasearch to help save lives.

Dr Amy McCart Reed

UNIVERSITY OF QUEENSLAND

New biomarkers to predict treatment response in patients with high-risk aggressive breast cancer

Read more

expand_more expand_less

Patients with aggressive breast cancers, including those with large tumours, high-grade triple negative or HER2 positive breast cancers are at high risk of treatment resistance and of the cancer returning after treatment, leading to poor survival outcomes. These patients often receive therapy before tumour removal (termed neoadjuvant therapy) aimed at reducing the size of the cancer prior to surgery. Currently, there are few biomarkers to predict which patients will respond to neoadjuvant therapy and those that will not, and response to neoadjuvant treatment is an indicator of patient outcome.

This project, led by Dr Amy McCart Reed (University of Queensland), will use cutting-edge genomic techniques to identify markers of treatment response or resistance. The study also aims to identify the most effective genomic technology, for personalised medicine, to profile individual tumours to match patients with the best therapy.

Prof Kum Kum Khanna

QIMR BEGHOFER MEDICAL RESEARCH INSTITUTE

Repurposing an arthritis drug for the treatment of metastatic triple negative breast cancer

Read more

expand_more expand_less

The spread of breast cancer to the brain is a major cause of mortality for patients with triple negative breast cancer (TNBC). In this study Prof Kum Kum Khanna (QIMR Berghofer Medical Research Institute) will examine whether Auranofin, a drug proven to be safe for the treatment of rheumatoid arthritis and can cross the blood-brain barrier, can be repurposed for the treatment of metastatic TNBC. Auranofin will be tested in combination with other FDA approved anti-cancer drugs known to reach the brain to identify new combination therapies for the treatment for metastatic TNBC.

YOUR DONATIONS ARE MAKING A DIFFERENCE

Where your money goes

Proceeds from the Mother’s Day Classic will be donated to the National Breast Cancer Foundation (NBCF) and the Ovarian Cancer Research Foundation (OCRF) to help to create a better tomorrow for those affected by breast and ovarian cancers.

When you sign up to the Mother’s Day Classic, you can choose where your money goes. Whether it’s the National Breast Cancer Foundation or the Ovarian Cancer Research Foundation or both, your support will help save lives.